The feasibility of intracellular mdr1 mRNA expression detection with radiolabeled antisense oligonucleotide (ODN) was investigated in the murine leukemia cell line, P388/S, and its subclonal, adriamycin-resistant cell line, P388/R. Methods: The expression level of mdr1 mRNA was analyzed by reverse transcription-polymerase chain reaction (RT-PCR). Existence of the multidrug resistance (MDR) phenomenon was assessed via cellular uptake of 99m Tc-sestamibi (MIBI), a known substrate for P-glycoprotein. A 15-mer phosphorothioate antisense ODN complementary to the equences located at −1 to 14 of mdr1 mRNA and its corresponding sense ODN were conjugated with the cyclic anhydride of diethylene triamine penta-acetic acid (cDTPA) via an amino group linked to the terminal phosphate at the 5′ end at pH 8-9. The DTPA-ODN complexes at concentrations of 0.1-17.4 µM were reacted with 111 InCl 3 at pH 5 for 1 h. The hybridization affinity of labeled ODN was evaluated with size-exclusion highperformance liquid chromatography following incubation with the complementary sequence. Cellular uptake of labeled ODN was examined in vitro. Furthermore, enhancing effects of synthetic lipid carriers (Transfast) on transmembrane delivery of ODN were assessed. Results: P388/R cells displayed intense mdr1 mRNA expression in comparison with P388/S cells. 99m Tc-MIBI uptake in P388/S cells was higher than that in P388/R cells. Specific radioactivity up to 1,634 MBq/nmol was achieved via elevation of added radioactivity relative to ODN molar amount. The hybridization affinity of antisense 111 In-ODN was preserved at approximately 85% irrespective of specific activity. 
Introduction
The multidrug resistance (MDR) phenomenon is one of the major causes of chemotherapeutic failure in the treatment of malignancies. Numerous studies have documented the involvement of ATP-dependent cassette transporters, such as P-glycoprotein/MDR1 (P-gp) and MDR-associated protein [1] [2] [3] . When these proteins are present on the cell membrane, chemotherapeutic agents are expelled from tumor cells rapidly; consequently, the cytotoxic effect of these agents is abolished.
Biopsy combined with molecular biological analysis or immunocytochemical techniques is beneficial for the detection of such proteins; however, technical difficulties and possible sampling error may lead to incorrect diagnoses. Nuclear medicine imaging involving the cationic compound, 99m Tc-sestamibi (MIBI), can be the modality of choice in terms of prediction of chemotherapeutic effects on malignancies [4, 5] . Intensity of 99m Tc-MIBI uptake in tumors can reflect the functional status of these transporters as 99m Tc-MIBI acts as a substrate of transporter P-gp; that is, tumors assimilating lower quantities of 99m Tc-MIBI are less likely to respond to chemotherapy. However, given that delineation of tumors with 99m Tc-MIBI scintigraphy is a multifactorial phenomenon, development of an imaging method specific to transporter function is required to assess precisely MDR of tumors related to transporter proteins.
Owing to its specific characteristics in targeting, single-strand oligonucleotide (ODN) may be a potential candidate for future clinical imaging. Several studies have demonstrated accumulation of 111 In-ODN in tumor cells via various types of target [6, 7] ; however, in terms of clinical application, problems remain, such as the difficulty in radiolabeling ODN to a high specific activity and inefficient transmembrane delivery [8] .
The current investigation attempted to synthesize a radiolabeled phosphorothioated ODN complementary to mouse mdr1 mRNA. In addition, the uptake kinetics of the labeled ODN was examined in a murine leukemia cell line and its subclonal MDR cell line in order to determine the feasibility of imaging of mdr1 mRNA.
Materials and methods

Reagents
Standard chemicals, which were obtained commercially, were utilized without purification. 111 InCl 3 was a gift from Nihon Mediphysics Co. (Nishinomiya, Japan). 99m Tc-pertechnetate was produced with a 99 Mo-99m Tc radionuclide generator (Daiichi Radioisotope Institute, Tokyo, Japan). All solutions were sterilized by filtration through a 0.22-µm filter (MILLEX-GV, Millipore, France). All tubes and pipette tips were autoclaved prior to use.
A 15-mer antisense ODN (AS-ODN) [(5′-TCTTCAAACTC-CATC-3′)], complementary to the sequences located at −1 to 14 of mdr1 mRNA, and its corresponding sense sequences (S-ODN) [(5′-GATGGAGTTTGAAGA-3′)] were obtained commercially (Grana, Tokyo, Japan). ODNs were phosphorothioated from the 5′ to the 3′ end to enhance resistance against exonuclease and endonuclease digestion. An amino group was linked to the terminal phosphate group at the 5′ end position through a 6-member methylene spacer. Following solubilization in autoclaved nanopure water, aliquots containing 370 µg of ODN were stored at −80°C.
Cell lines
Murine leukemia P388/S and its subclonal doxorubicin-resistant cell lines (P388/R) were provided by the Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. The P388/R cell line was developed by repeated treatment with doxorubicin in murine ascites [9] . Cells were passed through female BALB/c × DBA/2 (CDF1) mice (Nihon SLC, Hamamatsu, Japan) by peritoneal injection and harvested 6-7 days after implantation [9] .
99m Tc-MIBI uptake in P388 cells Intracellular uptake of 99m Tc-MIBI (Daiichi Radioisotope Laboratory, Tokyo, Japan), a substrate of transporter P-gp, was measured. Cells were washed twice with chilled phosphate-buffered saline (PBS) and re-suspended in RPMI 1640 medium (Nissui Seiyaku, Tokyo, Japan) supplemented with 10% fetal calf serum (FCS). Aliquots of the cell suspension at 3.0×10 6 cells/0.5 ml were introduced to tubes.
99m Tc-MIBI was prepared with 2 ml of 99m Tc-pertechnetate (370 MBq/ml). 99m Tc-MIBI solution (10 µl) was added to the cell suspension. Media were incubated at 37°C in a water-saturated atmosphere containing 5% CO 2 . At 0.5, 1, 2 and 4 h, the incubation was terminated by centrifugation at 400g for 5 min followed by aspiration of the supernatant. Cell pellets were washed with chilled PBS twice; subsequently, radioactivity of the cell pellets was measured in a well-type gamma counter to determine percentage uptake of 99m Tc-MIBI into the cells. Triplicate samples were measured at each time point. Viability of cells was assessed by trypan blue exclusion at the conclusion of experiments.
Detection of mdr1 mRNA expression by reverse transcription-polymerase chain reaction analysis Poly(A) + RNAs, which were isolated from subcutaneous tumors of P388/S and P388/R cells in BALB/c nu/nu naked mice (Nihon SLC, Hamamatsu, Japan) with a QuickPrep mRNA purification kit (Amersham Biosciences, Buckinghamshire, UK), were analyzed with a SuperScript One-Step RT-PCR kit with Platinum Taq (Invitrogen Corp., Carlsbad, CA, USA). Primers for detection of mRNA coding for mouse mdr1 were 5′-CGAGCCTGGTG-GTCAGT-3′ representing bases 2449-2432 and 5′-TGCATAC-AACCAGTGTTTG-3′ representing bases 2161-2179 [10] . The amount of RNA template and the cycle number for amplification were selected in quantitative ranges at which reactions proceeded in linear fashion: 50 ng of template and 30 cycles. The temperatures and time periods employed for melting, annealing and extension were 94°C, 15 s, 57°C, 30 s and 72°C, 60 s, respectively. An aliquot of each RT-PCR reaction mixture was electrophoresed on 2% agarose gel and stained with ethidium bromide. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as an internal reference to ensure integrity of the RNAs. Primers for detection of mouse GAPDH mRNA (accession no. M32599) were 5′-GGT-GAAGGTCGGTGTGAACGGATT-3′ and 5′-ATGCCAAAGTTG-TCATGGATGACC-3′.
DNA conjugation
The cyclic anhydride of diethylene triamine penta-acetic acid (cDTPA) [(Wako, Tokyo, Japan)] was conjugated to ODN according to a protocol similar to that described by Fujibayashi et al. [11] . ODN (78 nmol) was dissolved in H 2 O (1.0 mM) and mixed with 3.9-4.2 mg of Na 3 PO 4 ·12H 2 O. The mixture was then incubated with 3.14 µmol of cDTPA (40 times in excess of ODN) for 1 h at 37°C. Final pH was maintained at 8.0-9.0. The reaction mixture was diluted to 1 ml with H 2 O and applied to a Sep-Pak C 18 cartridge (Waters, Milford, MA) pretreated with 5 ml of acetonitrile, 10 ml of H 2 O and 10 ml of 0.15 M NaCl solution. The eluate was re-applied to the cartridge twice. The cartridge was then washed with 20 ml of H 2 O, after which the ODN fraction was eluted with 3 ml of 30% acetonitrile (v/v) in H 2 O. Fractions (1 ml) were collected and the absorbance (260 nm) of each fraction was measured. 111 In labeling of ODN Conjugated ODN solution and 111 InCl 3 solution (pH 0.17) were adjusted in advance to pH 5.0 with 0.1 M citrate buffer (pH 5.0). DTPA-conjugated ODN (concentrations ranged from 0.10 µM to 17.37 µM) was introduced to 111 InCl 3 , followed by incubation for 1 h at room temperature. A 30-fold excess of DTPA was added to quench free 111 In 3+ after a 1-h incubation. The preparation was routinely analyzed by size-exclusion high-performance liquid chromatography (HPLC). Following collection, radioactivity of fractions (0.5 ml) was measured in a well-type gamma counter. When labeling efficiency was less than 90%, 111 In-labeled ODN was purified with a Sep-Pak C 18 cartridge. To assess the extent of nonspecific labeling, DTPA-unconjugated ODN was also introduced to 111 In chloride involving the identical labeling procedure [12] .
In vitro stability analysis 111 In-labeled ODN was incubated in PBS, a 15-fold excess DTPAcontaining medium, or human serum at 37°C. Incubated solutions were analyzed with size-exclusion HPLC at 24 h.
Hybridization affinity
In order to assess the hybridization affinity of labeled ODN to its complementary sequences, labeled S-ODN and AS-ODN were incubated with a 15-fold excess of their unconjugated identical and complementary sequences in a 5× SSPE solution at 37°C overnight. The incubated mixture was then applied to size-exclusion HPLC. Fractions of 0.15 ml/10 s were collected and radioactivity was measured in a well-type gamma counter.
Vectorization
The carrier for delivery enhancement of ODN in the current investigation was a Transfast reagent (Promega, Madison, WI), which consists of a synthetic cationic lipid, (+)-N,N [2-hydroxyethyl-N-[2,3-di(tetradecanoyloxy)propyl] ammonium iodide, and a neutral lipid, L-dioleoyl phosphatidylethanolamine (DOPE). A quantity of the carrier at a charge ratio of 1:1 or 2:1 (carrier/ODN) was mixed with labeled S-ODN and AS-ODN and placed at room temperature for 10 min. Subsequently, vectorized ODNs were employed for cellular uptake experiments.
ODN uptake P388/S and P388/R cells prepared from murine ascites were suspended at 6×10 6 cells/ml. 111 In-labeled S-ODN and AS-ODN at a specific radioactivity of about 2.45 MBq/nmol were incubated with P388/S and P388/R cells in RPMI 1640 medium supplemented with 10% FCS. Viability of cells was assessed by trypan blue extension at the conclusion of experiments.
To determine whether the ODN concentration would affect the extent of 111 In-labeled ODN uptake, P388/R cells were incubated with AS-ODN at concentrations ranging from 0.57 nM to 73 nM for 1 h at 37°C. In order to evaluate the uptake kinetics of ODN, 111 In-labeled AS-ODN (7.3 nM) was incubated in the P388/R cell suspension for up to 24 h [13, 14] . Based on the results of these two sets of experiments, comparison of the uptake of 111 In-labeled S-ODN and AS-ODN in P388/S and P388/R cells was performed at 7.3 nM up to 4 h [13, 15, 16] .
The delivery-enhancing effect of the carrier was examined by incubation of AS-ODN with carrier at charge ratios of 1:1 or 2:1 (carrier/DNA) in a P388/R cell suspension. In all the aforementioned experiments, aliquots of ODN-containing cell suspension were removed for centrifugation at each time point; in addition, cell pellets were washed twice with chilled PBS. Radioactivity associated with cells was measured in a well-type gamma counter. Uptake of ODN was expressed as percentage of applied radioactivity per 10 6 cells. Each experiment was conducted in triplicate and repeated twice.
Statistics
All values were expressed as the mean and standard deviation (SD) of the data. The results were analyzed with the MannWhitney test. The level of significance was set at 5%.
Results
Trypan blue exclusion test revealed that >95% of the incubated cells remained alive after a 4-h incubation. 99m Tc-MIBI uptake in P388/S cells was higher than that in P388/R cells throughout the observation period (Table 1) .
P388/R cells displayed intense expression of mdr1 mRNA in comparison with P388/S cells (lanes 1 and 2 in Fig. 1) . Intensity of the GAPDH band at 500 bp was similar for the two cell lines (lanes 3 and 4 in Fig. 1 ), excluding the possibility of inequality of amplification during the PCR process and of errors associated with PCR product load onto the agarose gel. Following the increase in added radioactivity relative to ODN molar amount, specific radioactivity up to 1,634 MBq/nmol was achieved (Fig. 2) . However, labeling efficiency declined from 92% (specific radioactivity 2.45 MBq/nmol) to 37% (specific radioactivity 1,634 MBq/nmol) in proportion to the elevation of added radioactivity/ODN ratio from 2.67 MBq/nmol to 4,361 MBq/nmol. Control labeling of DTPA-unconjugated ODN under identical conditions revealed a labeling efficiency of <1%, indicating that nonspecific binding of 111 In was negligible.
HPLC analysis indicated that breakdown of 111 Inlabeled ODN did not occur at 37°C in PBS, excess DTPA-containing medium or human serum. In human serum, 72.6% of radioactivity was associated with larger molecules, probably albumin, at 24 h.
As shown in Fig. 3 , when AS-ODN labeled at a specific radioactivity of 2.45 MBq/nmol was incubated with AS-ODN, peak radioactivity appeared in fraction no. 16, concordant with single-strand AS-ODN; this observation indicated that hybridization did not occur. Upon incubation with S-ODN, peak radioactivity shifted to fraction no. 13 Uptake of AS-ODN in P388/R cells was 0.3-0.5% total dose/10 6 cells in the concentration range 0.57 nM to 73 nM for 1 h. ODN concentration exerted no obvious influence on uptake in P388/R cells (Fig. 4) .
In the absence of carrier incorporation, specific uptake of AS-ODN in P388/R cells did not occur, as shown in Table 2 ; uptake of AS-ODN in P388/R cells did not differ from that in P388/S cells. Furthermore, no difference was observed in uptake between S-ODN and AS-ODN in P388/R cells.
Extension of incubation to 24 h resulted in relatively unchanged uptake of AS-ODN in P388/R cells at 0.5-0.7% total dose/10 6 cells up to 7 h; however, uptake increased to 2% after 24 h (Fig. 5) . The trypan blue exclusion test revealed that >90% of the cells remained alive at 7 h; in contrast, >50% of the cells were dead at 24 h. The delivery-enhancing effect of 111 In-labeled AS-ODN in P388/R cells was assessed (Table 3) . Carrier incorporation significantly increased the cellular uptake of AS-ODN. The enhancing effect was more substantial at a charge ratio of 2:1 than at a charge ratio of 1:1.
With vectorization at a charge ratio of 2:1, which resulted in a positively charged ODN complex, uptake of 111 In-AS-ODN was significantly higher in P388/R cells than in P388/S cells (Table 4) . Although uptake of 111 In-S-ODN was also significantly higher in P388/R cells than in P388/S cells, P388/R cells assimilated significantly more 111 In-AS-ODN than 111 In-S-ODN (Table 4) .
Discussion
As reported in previous studies [4, 5] , higher uptake of 99m Tc-MIBI in P388/S cells in comparison to P388/R cells (Table 1) phenomenon in P388/R cells. MDR was demonstrated by the presence of mdr1 mRNA in these cells (Fig. 1) . Radionuclides suitable for imaging, such as 111 In and 99m Tc, are metallic elements; therefore, conjugation of ODN with an appropriate chelate serving as a bridge to link radioelements is necessary [9, 12] . Derivatives of DTPA are most commonly used for this purpose. Hnatowich [8] and Karamychev et al. [14] achieved high specific radioactivity employing 2,110-fold and 1,260-fold excesses of cDTPA for conjugation. However, such conjugation was characterized by markedly decreased pH of the reaction mixture owing to hydrolysis of cDTPA, which may cause degradation of ODN. In addition, elimination of DTPA molecules unbound to ODN required repeated purification on a separation cartridge. In our preliminary conjugation experiments, pH >10 or <7 inhibited conjugation of DTPA to ODN, resulting in a low labeling efficiency of <10%. Consequently, the labeling method described by Fujibayashi et al. [11] was modified via adjustment of the amount of added Na 3 PO 4 ·12H 2 O to maintain the pH of the reaction solution in the range of 8.0-9.0, which is optimal for the conjugation [12, 14] . On the basis of this modification, ODN conjugation with DTPA was achieved and purification of conjugated ODN was completed simply by single application of the reaction solution to a Sep-Pak C 18 cartridge. This conjugation afforded the realization of 111 In-labeled ODN possessing high specific radioactivity at considerable labeling efficiency (Fig. 2) .
Because the target mRNA copy usually ranges between 1 and 1,000 per cell [17, 18] at steady state, it cannot be expected that 111 In-ODN can enter into cells and bind with the target mRNAs in a great amount within a short time. The number of 111 In-ODN molecules delivered into cells was calculated to be lower than 500 per cell in this study. Accordingly, 111 In-ODN with high specific radioactivity should be necessary to delineate lesions for in vivo imaging. This study has achieved radiolabeling with high specific radioactivity up to 1,634 MBq/nmol, which is much higher than documented previously [11, 14, 19] . Compounds possessing high specific activity can afford a high signal intensity in targeted lesions, which surely improves the signal-tobackground ratios, enhancing lesion delineation.
Analysis by size-exclusion HPLC demonstrated the stability of 111 In-labeled ODN in human serum. Non-specific binding of 111 In-labeled ODN with serum proteins, including albumin, was observed. Although such binding increases particle size, it can also protect ODN from degradation by nucleases [12] .
Preservation of hybridization affinity of ODN following chemical modifications during the processes of DTPA-conjugation and radiolabeling is essential for successful antisense targeting. HPLC analysis revealed that approximately 85% of the 111 In-labeled ODN at a specific radioactivity up to 1,634 MBq/nmol maintained its hybridization affinity (Fig. 3) .
Receptor-mediated endocytosis or pinocytosis has been postulated as the possible mechanism by which phosphorothioate ODN enters tumor cells [19] . However, owing to their inherent negative charge, native ODN and phosphorothioate ODN suffer from poor intracellular entry.
Several studies have demonstrated intracellular uptake of ODN after 24-h incubation [6, 20] . In the current investigation, uptake of AS-ODN in P388/R cells was low up to 7 h; however, uptake significantly increased at 24 h (Fig. 5) . In comparison, the trypan blue exclusion test revealed that >90% of the incubated cells remained alive at 7 h; however, more than half of these cells were dead at 24 h. These results indicate that the net negative charge of the cell membrane inhibited transmembrane delivery of ODN up to 7 h; moreover, ODN readily entered the cells following the loss of cell membrane integrity at 24 h. Therefore, low transmembrane delivery due to a negative charge interaction between ODN and the cell membrane is likely a major factor leading to low uptake of 111 In-AS-ODN in P388/R cells despite the existence of mdr1 mRNA.
Entry of high concentrations of antisense ODN into target cells is a prerequisite for gene imaging [21] . The results in Table 2 emphasize the necessity of increasing transmembrane delivery. Physical disruption of cell membranes is an alternative strategy to improve cellular delivery. However, it cannot be expected that it will ultimately be of value in clinical imaging owing to the difficulty in its in vivo application. Chemical modifications to neutralize the negative charge of ODN by association with nonviral carriers appear to improve the cellular uptake of ODN significantly [22] [23] [24] [25] . Such carriers are primarily cationic lipids, designed to contain the ODN molecule within a lamellar structure, which allows the lipid to coat the ODN by charge interactions. The carrier employed in the current investigation is a lipid complex consisting of a cationic and a neutral lipid. The cationic lipid permits binding of the lipid-ODN complex to the cell membrane; in addition, based on the presence of the neutral lipid, cells engulf the lipid-ODN complex attached to the cell membrane, which leads to introduction into the cytoplasm. Inside the cells, the neutral lipid disrupts endosome trapping, which allows ODN to escape into the cytoplasm to hybridize with its target mRNA [23] .
After binding with the carrier at net neutral (carrier/ODN 1:1) and positive charge (carrier/ODN 2:1), intracellular uptake of 111 In-labeled ODN increased by a maximum 2.3-fold and 6.4-fold, respectively ( Table 3) . The increase in uptake following binding with the carrier is in accordance with our hypothesis that the negative charge of cell membranes blocks ODN delivery. Both uptake by endocytosis itself and delivery enhancement by lipidic carrier are neither tissue-specific nor cellspecific; therefore, elevated uptake of 111 In-AS-ODN in P388/R cells is believed to occur as a result of duplex formation of AS-ODN with intracellular mdr1 mRNA.
In summary, the current investigation addressed systemically and comprehensively factors affecting antisense targeting, from the existence of target mRNA to the transmembrane delivery of ODN. The existence of the MDR phenomenon and of target mdr1 mRNA were confirmed by 99m Tc-MIBI, RT-PCR, and antisense targeting. This seems to be the first time that conjugation of ODN with DTPA has been achieved in a simple way that enables radiolabeling at high specific radioactivity without reducing its hybridization ability. In addition, this is the first report addressing the function of Transfast in increasing 111 In-ODN intracellular uptake. Information provided by the current investigation may facilitate in vivo gene imaging by targeting mdr1 mRNA.
